https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.htmlOne place for news and notices from 2 countries/regions: Taiwan, 176 items from 5 sources; Japan, 136 items from 1 source.One edition every 180 minutes: every item from every source received in the period, with the original link.en https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3101788https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3101788Tue, 29 Sep 2026 17:10:02 +0900Taiwan鉅亨網《紐約時報》專欄批評川普政府與國防部長赫格塞斯在對伊朗戰爭中嚴格限制媒體，導致美國民眾難以掌握真實戰況。CBS取得現役軍人匿名提供的照片，顯示美軍基地與軍機遭伊朗攻擊嚴重受損，與官方說法不符。文章強調媒體管制侵害新聞自由，也切斷軍人與社會的連結，影響民主問責。 https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102213https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102213Tue, 29 Sep 2026 01:00:00 +0900Taiwan環球生技月刊Global Bio & Investment Monthly reported biotech stock movements on September 29, 2026. 浩鼎, 基米-創 and 漢達 were the top 3 gainers, while 北極星藥業-KY, 共信-KY and 五鼎 were among the biggest decliners. https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102212https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102212Tue, 29 Sep 2026 01:00:00 +0900Taiwan環球生技月刊Institutional activity on September 29, 2026 showed net foreign buying of 高端疫苗, 國光生 and 晟德, while 沛爾生醫*-創, 康霈* and 北極星藥業-KY saw net selling. https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102211https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102211Tue, 29 Sep 2026 01:00:00 +0900Taiwan環球生技月刊09/29 biotech stock activity: 安立璽榮-KY receives TFDA approval to conduct a clinical trial of a new Alzheimer's drug; 北極星藥業-KY changes the use of its capital-raising proceeds; 施吉生技 plans to partner with 亞太智能機器 to develop a medical AI language model; 長佳智能 and 敏成健康 plan share buybacks. https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102210https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102210Tue, 29 Sep 2026 01:00:00 +0900Taiwan環球生技月刊敏成健康 (4431) announced it will buy back 1,826,775 treasury shares starting October 1, at a price range of 15 to 25 yuan. https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102209https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102209Tue, 29 Sep 2026 01:00:00 +0900Taiwan環球生技月刊國鼎 (4132) Vice Chairman and Director Chen Yu-chun resigned on 115/09/24, resulting in one-third turnover on the board. https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102208https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102208Tue, 29 Sep 2026 01:00:00 +0900Taiwan環球生技月刊北極星藥業-KY announced the appointment of Tseng Hsiao-hsuan as its new head of internal audit. The event date was 115/09/29. https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102207https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102207Tue, 29 Sep 2026 01:00:00 +0900Taiwan環球生技月刊北極星藥業-KY (6550) announced that the remaining proceeds from its Year 113 cash capital increase will be redirected to bolster working capital, with an expected payback period of 8 years. https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102206https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102206Tue, 29 Sep 2026 01:00:00 +0900Taiwan環球生技月刊浩泰(4131)董事長訂9/29為員工認股權憑證轉換普通股增資基準日 https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102200https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102200Tue, 29 Sep 2026 01:00:00 +0900Taiwan環球生技月刊浩泰(4131)董事長訂9/29為員工認股權憑證轉換普通股增資基準日。 https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102199https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102199Tue, 29 Sep 2026 01:00:00 +0900Taiwan環球生技月刊偉喬生醫 won the “SME Group” award at the 22nd Taiwan Golden Root Awards and was received by President Lai Ching-te; the company is advancing its capital market plans and developing one-stop CRDMO services. https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102258https://ainews.idaeo.ai/180m/20260929-18/index-en-p4.html#n3102258Tue, 29 Sep 2026 18:20:08 +0900TaiwanHeho健康疾管署 announced that the first phase of the 2026 publicly funded influenza and COVID vaccination program will begin on October 1, with the second phase starting November 2 and opening vaccination to adults ages 50 to 64 without high-risk chronic diseases.